19.04.2012 • NewsAlbemarlesales and profitsQ1 2012

Albemarle Profits Up

Chemical maker Albemarle's first quarter earnings rose, and beat Wall Street's expectations, on strong sales of catalysts used by petroleum refiners.

Sales of specialty materials have become a niche industry for Albemarle and its peers, with customers increasingly willing to pay more for them.

For the quarter ended March 31, the company said net income rose to $108 million, or $1.20 per share, from $106.6 million, or $1.15 a share, in the year-ago period.

Analysts, on average, expected earnings of $1.16 per share, according to Thomson Reuters I/B/E/S.

Sales rose 2% to $711.7 million. Analysts expected $730.4 million.

Sales of its catalysts rose 13% to $293.5 million from the same period last year.

Albemarle also said that sales in its fine chemistry unit, which supplies material for the pharmaceutical industry, increased 7% to $190 million.

Sales of polymer solutions fell 12% to $228.1 million.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.